Celularity (CELU) Financials: History & Chart

Celularity Inc.(CELU)

Biotechnology · Florham Park, NJ

$1.56-0.15 (-8.77%)

Delayed quote: Oct 6, 2026, 3:14 PM EDT

About Celularity Inc.

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.

Florham Park, NJ

115 employees

www.celularity.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Joseph Hariri

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	18.97M	3.85M	4.10M	5.28M	5.74M	11.43M	18.13M	9.30M	12.11M
Cost of Goods Sold	3.87M	1.06M	-4.45M	2.02M	5.24M	3.55M	7.34M	3.88M	2.12M
Gross Profit	15.10M	2.79M	8.56M	3.27M	494K	7.87M	10.79M	5.41M	9.99M
Gross Profit Margin	79.6%	72.5%	208.5%	61.8%	8.6%	68.9%	59.5%	58.2%	82.5%
Total Operating Expenses	76.06M	12.92M	30.61M	16.17M	16.36M	18.36M	20.07M	16.94M	20.16M
Research & Development	14.29M	2.99M	3.35M	4.60M	3.35M	3.73M	3.83M	3.92M	3.80M
Selling, General & Administrative	46.17M	9.16M	15.06M	9.31M	12.63M	14.26M	16.06M	12.65M	15.91M
Operating Income (EBIT)	-60.95M	-10.13M	-22.06M	-12.90M	-15.86M	-10.49M	-9.28M	-11.53M	-10.18M
Operating Margin	-321.3%	-263.5%	-537.5%	-244.1%	-276.6%	-91.8%	-51.2%	-124.0%	-84.0%
Income Before Tax (EBT)	-71.28M	675K	-24.36M	-23.08M	-24.52M	-19.75M	-13.29M	-16.10M	-6.49M
Interest Income	248K	62K	62K	62K	62K	76K	77K	77K	67K
Interest Expense	3.96M	-352K	897K	1.48M	1.94M	2.44M	1.81M	1.75M	1.55M
Other Income/Expense	-10.33M	10.81M	-2.30M	-10.18M	-8.66M	-9.27M	-4.01M	-4.57M	3.69M
Net Income	-71.28M	675K	-24.36M	-23.07M	-24.52M	-19.75M	-13.29M	-16.10M	-6.49M
Income Tax Expense	0.00	0.00	3K	-3K	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-375.8%	17.6%	-593.6%	-436.7%	-427.5%	-172.9%	-73.3%	-173.2%	-53.6%
EBITDA	-53.85M	-8.54M	-20.25M	-11.03M	-14.03M	-8.65M	-7.40M	-9.63M	-8.18M
EBITDA Margin	-283.9%	-221.9%	-493.5%	-208.8%	-244.6%	-75.7%	-40.8%	-103.6%	-67.5%
Depreciation & Amortization	7.10M	1.60M	1.80M	1.87M	1.83M	1.83M	1.88M	1.89M	2.00M
EPS Basic	-2.83	0.02	-0.95	-0.88	-1.02	-0.84	-0.59	-0.73	-0.30
EPS Diluted	-2.83	0.02	-0.95	-0.88	-1.02	-0.84	-0.59	-0.73	-0.30
Weighted Average Basic Shares	29.07M	29.07M	25.60M	26.35M	24.02M	23.53M	22.35M	21.98M	21.85M
Weighted Average Diluted Shares	30.30M	30.30M	25.60M	26.35M	24.02M	23.53M	22.35M	21.98M	21.85M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	26.55M	54.22M	22.77M	17.98M	21.34M	14.28M	21.15M	17.55M
Cost of Goods Sold	6.36M	14.99M	16.02M	19.66M	9.65M	4.93M	6.32M	6.55M
Gross Profit	20.19M	39.23M	6.75M	-1.69M	11.68M	9.35M	14.82M	11.00M
Gross Profit Margin	76.0%	72.4%	29.7%	-9.4%	54.8%	65.5%	70.1%	62.7%
Total Operating Expenses	81.50M	77.59M	199.04M	23.91M	120.74M	161.27M	278.95M	1K
Research & Development	15.03M	17.39M	30.46M	78.36M	88.35M	52.71M	46.05M	29.06M
Selling, General & Administrative	51.27M	58.64M	50.58M	66.02M	71.34M	31.34M	41.79M	1K
Operating Income (EBIT)	-61.31M	-38.36M	-192.29M	-25.60M	-109.06M	-151.93M	-264.13M	-1K
Operating Margin	-230.9%	-70.7%	-844.4%	-142.4%	-511.2%	-1064.0%	-1249.0%	-0.0%
Income Before Tax (EBT)	-91.71M	-57.89M	-196.28M	14.21M	-100.10M	-212.93M	-267.99M	-1K
Interest Income	262K	331K	320K	365K	332K	370K	694K	628K
Interest Expense	6.75M	6.26M	3.02M	N/A	3.17M	2.35M	N/A	N/A
Other Income/Expense	-30.41M	-19.53M	-4.00M	39.80M	8.96M	-61.01M	-3.87M	2.00
Net Income	-91.80M	-57.89M	-196.29M	14.19M	-100.12M	-208.23M	-211.88M	-1K
Income Tax Expense	3K	0.00	10K	13K	20K	-4.70M	-56.11M	0.00
Net Profit Margin	-345.8%	-106.8%	-862.0%	79.0%	-469.3%	-1458.4%	-1001.9%	-0.0%
EBITDA	-54.01M	-30.44M	-182.96M	-16.16M	-100.24M	-143.75M	-257.94M	4.79M
EBITDA Margin	-203.4%	-56.1%	-803.5%	-89.9%	-469.8%	-1006.8%	-1219.8%	27.3%
Depreciation & Amortization	7.29M	7.92M	9.32M	9.44M	8.82M	8.17M	6.19M	4.79M
EPS Basic	-3.59	-2.64	-11.02	1.01	-7.87	-113.06	-88.75	0.00
EPS Diluted	-3.59	-2.64	-11.02	0.95	-7.87	-113.06	-88.75	0.00
Weighted Average Basic Shares	25.60M	21.89M	17.81M	13.99M	12.73M	1.84M	2.39M	3.59M
Weighted Average Diluted Shares	25.60M	21.89M	17.81M	14.98M	12.73M	1.84M	2.39M	3.59M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.